

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040: <i>Research, Development, Test & Evaluation, Army / BA 4: Advanced Component Development & Prototypes (ACD&P)</i>	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>
---	--

COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
Total Program Element	-	22.825	31.962	33.503	-	33.503	28.678	28.186	33.518	34.412	Continuing	Continuing
808: <i>DoD Drug & Vacc Ad</i>	-	8.701	15.997	14.914	-	14.914	14.324	14.310	16.502	16.942	Continuing	Continuing
811: <i>Mil HIV Vac&Drug Dev</i>	-	1.036	0.965	0.638	-	0.638	0.810	0.842	0.882	0.905	Continuing	Continuing
836: <i>Field Medical Systems Advanced Development</i>	-	12.819	15.000	17.951	-	17.951	13.544	13.034	16.134	16.565	Continuing	Continuing
VST: <i>MEDEVAC Mission Equipment Package (MEP) - Adv Dev</i>	-	0.269	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	0.269

Note

No PE or project change in FY17.

A. Mission Description and Budget Item Justification

This program element (PE) funds development of medical materiel within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet future force requirements identified within concept documents and organizational structures. This Program Element also provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. The Projects supported by this PE are:

(PROJ 808) funds development of candidate medical countermeasures for infectious diseases of military relevance. Efforts include vaccines, drugs, diagnostic kits/ devices, and insect control measures. These funds support human clinical efficacy trials of the drug/vaccine in a larger group that are designed to assess performance and to continue safety assessments in a larger group of volunteers. Products from this project will transition to PE 0604807A, Project 849.

(PROJ 811) funds the development of military relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and investigate the appropriate dose for therapeutic use. Products from this project will transition to PE 0604807A, Project 812.

(PROJ 836) funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project also funds the human clinical trials that test the safety and effectiveness of biologics, devices and demonstration. Clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations. Products from this project will transition to PE 0604807A, Project 832.

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2017 Army	Date: February 2016
---	----------------------------

Appropriation/Budget Activity 2040: <i>Research, Development, Test & Evaluation, Army / BA 4: Advanced Component Development & Prototypes (ACD&P)</i>	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>
---	--

(PROJ VS7) funds program upgrades, retrofits, trains, and sustains the fleet of Medical Evacuation legacy helicopters that continue to play a major role in Iraq and Afghanistan. The approved force design increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies. All products from this project will transition to PE 0604807A Project VS8.

These projects are managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command.

B. Program Change Summary (\$ in Millions)	<u>FY 2015</u>	<u>FY 2016</u>	<u>FY 2017 Base</u>	<u>FY 2017 OCO</u>	<u>FY 2017 Total</u>
Previous President's Budget	23.647	31.962	35.423	-	35.423
Current President's Budget	22.825	31.962	33.503	-	33.503
Total Adjustments	-0.822	0.000	-1.920	-	-1.920
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.822	-			
• Adjustments to Budget Years	-	-	-1.920	-	-1.920

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army										Date: February 2016		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>			
COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
808: <i>DoD Drug & Vacc Ad</i>	-	8.701	15.997	14.914	-	14.914	14.324	14.310	16.502	16.942	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

Note

Not applicable for this item.

A. Mission Description and Budget Item Justification

This project funds development of candidate medical countermeasures for infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices, and to determine if insects are infected with pathogenic organisms capable of infecting service members/preventive medicine measures. These funds support human clinical effectiveness (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works, and to continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and accelerated recovery time once diagnosed; to enhance battlefield readiness. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2015	FY 2016	FY 2017
Title: DoD Drug and Vaccine Advanced Development	8.701	15.997	14.914
Description: Funding is provided for the following effort in the development of candidate medical countermeasures for military relevant infectious disease.			
FY 2015 Accomplishments: Topical Antileishmanial Cream (TLC, Paromomycin/Gentamicin): Topical Antileishmanial Cream transitioned in FY14 to PE 0604807A Project 849 (Drugs and Vaccines - 6.5) after completion of the site development efforts for Phase 3 (expanded safety, efficacy, and dosing study) New World clinical trial. Expanded Access Treatment Program and continued until FDA approved product is available. Dengue Tetravalent Vaccine: Dengue Tetravalent Vaccine transitioned in FY14 to PE 0604807A Project 849 after completion of volunteer follow up and data analysis on pivotal Phase 3 safety and effectiveness clinical trials. Preventive Medicine Products: These products fall into the category military operational requirements and are Commercial-Off-The-Shelf (COTS). As such, they have moved to a more appropriate Program Element (PE 0603807A Project 836 or PE 0604807A Project 832) and will be listed as separate products when they are considered for military use.			
FY 2016 Plans:			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army	Date: February 2016
--	----------------------------

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>
--	--	---

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2015	FY 2016	FY 2017
<p>Dengue Tetravalent Vaccine: Continue to fund Dengue Tetravalent Vaccine until FY18 for additional two-year volunteer follow-up and data analysis on pivotal Phase 3 safety and effectiveness clinical trials required by the Thai Ministry of Public Health. Infectious Disease Diagnostic: Transition products from S&T in FY16. Begin preparation for field testing and evaluation of several product candidates to include: Scrub Typhus, Rickettsiae, and Sand Fly Fever. Dengue Vaccine Block II: Transition from S&T in FY16. Transition from Military Infectious Diseases S&T funding and prepare for Phase 2 safety and efficacy trial (24 to 300 subjects) of vaccine candidate in an adult/military population. Treatment for Resistant Wound Infections: Products will transition from S&T in FY16. Transition from Military Infectious Diseases S&T funding and begin preparation for safety and efficacy trials of drug candidate for the Treatment for Resistant Wound Infections. Next Generation Malaria Prophylaxis: Initiate a retinal safety study in FY16 and continue to prepare the protocols for any required soldier specific studies that is needed. Arthropod Control/Surveillance: Begin preparation for field testing and evaluation of several product candidates to include; Scrub Typhus, Rickettsiae, and Sand Fly Fever.</p> <p>FY 2017 Plans: Dengue Tetravalent Vaccine: Will transition to PE 0604807A Project 849 in FY17. Infectious Disease Diagnostic products: In FY17 products within this area will move to the Rapid Diagnostic and Detection Devices. Dengue Vaccine Block II: Will continue to prepare for Phase 2 safety and efficacy trial (24 to 300 subjects) of vaccine candidate in an endemic population and plan/prepare for phase 2 studies (safety and efficacy 24 to 300 subjects) involving adult military/traveler population. Preparation will include candidate formulation evaluation in dengue human challenge studies. Treatment for Resistant Wound Infections: Products will transition in FY17 from the Military Infectious Diseases Advanced Technology program. Will begin preparation for safety and efficacy trials of drug candidate for the Treatment for Resistant Wound Infections. Next Generation Malaria Prophylaxis: Will continue the retinal (eye) safety study started in FY16 and will continue to prepare the protocols for any required soldier specific studies for FDA review. Arthropod Control/Surveillance: In FY17 products within this area will move to the Rapid Diagnostic and Detection Devices. Rapid Diagnostic and Detection Devices: In FY17 the Infectious Disease Diagnostic and Arthropod Control/ Surveillance products have moved under this product title. Will continue field testing and evaluation of several product candidates to include: dengue, chikungunya and leptospirosis.</p>			
Accomplishments/Planned Programs Subtotals	8.701	15.997	14.914

C. Other Program Funding Summary (\$ in Millions)
N/A

Remarks

D. Acquisition Strategy
Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity	R-1 Program Element (Number/Name)	Project (Number/Name)
2040 / 4	PE 0603807A / <i>Medical Systems - Adv Dev</i>	808 / <i>DoD Drug & Vacc Ad</i>

E. Performance Metrics

N/A

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 808 / DoD Drug & Vacc Ad
--	---	--

Management Services (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Management Services Cost	Various	Not Applicable : Not applicable	17.390	0.965		1.280		2.130		-		2.130	Continuing	Continuing	Continuing
Medical Product Development Management Services Cost	PO	General Dynamics Information Technology, : Frederick MD	0.000	1.300		1.293		2.118		-		2.118	0	4.711	0
Subtotal			17.390	2.265		2.573		4.248		-		4.248	-	-	-

Product Development (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Cost	Various	Not applicable : Not applicable	24.717	1.270		2.632		2.036		-		2.036	Continuing	Continuing	Continuing
Product Development of Malaria Prophylaxis	Allot	TBD : TBD	0.000	1.010		-		-		-		-	0	1.010	0
Product Development of Malaria Prophylaxis	Allot	Armed Forces Research Institute of Medical Sciences : Cambodia	2.111	-		-		-		-		-	0	2.111	0
Product Development of Malaria Prophylaxis	Various	Walter Reed Army Institute of Research : Silver Spring, MD	3.000	-		-		-		-		-	0	3.000	0
Subtotal			29.828	2.280		2.632		2.036		-		2.036	-	-	-

Support (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Support Cost	Various	Not Applicable : Not applicable	9.652	0.997		2.545		2.527		-		2.527	Continuing	Continuing	Continuing

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>
--	--	---

Event Name	FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020				FY 2021			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
	Topical Antileishmanial Cream Expanded Access Treatment Pgm																											
Infectious Disease Diagnostics Assays Validation of point-of-care																												
Dengue Vaccine Block II Phase 2 safety trial preparation/perform																												
Arthropod Control / Surveillance Process Validation																												
Treatment for Resistant Wound Infections Phase 2 safety trial																												
Q Fever Vaccine IND and NDA package creation																												
D5P Next Generation Malaria Drug Clinical Studies																												
Oral Drug for Cutaneous Leishmaniasis Adult Indication Study																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 808 / <i>DoD Drug & Vacc Ad</i>
--	--	---

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Topical Antileishmanial Cream Expanded Access Treatment Pgm	2	2011	1	2017
Infectious Disease Diagnostics Assays Validation of point-of-care	1	2016	1	2022
Dengue Vaccine Block II Phase 2 safety trial preparation/perform	1	2016	4	2019
Arthropod Control / Surveillance Process Validation	1	2016	1	2022
Treatment for Resistant Wound Infections Phase 2 safety trial	1	2016	4	2019
Q Fever Vaccine IND and NDA package creation	1	2015	4	2016
D5P Next Generation Malaria Drug Clinical Studies	1	2016	4	2017
Oral Drug for Cutaneous Leishmaniasis Adult Indication Study	1	2016	4	2019

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army										Date: February 2016		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) 811 / <i>Mil HIV Vac&Drug Dev</i>			
COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
811: <i>Mil HIV Vac&Drug Dev</i>	-	1.036	0.965	0.638	-	0.638	0.810	0.842	0.882	0.905	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project funds development of militarily relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for the planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and to investigate the appropriate dose for therapeutic use. Development efforts are focused on militarily unique needs effecting manning, mobilization, and deployment.

The major contractor is Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2015	FY 2016	FY 2017
Title: Military HIV Vaccine & Drug Development	1.036	0.965	0.638
Description: This project funds advanced development research to develop candidate HIV vaccines, assess their safety and effectiveness in evaluations with human subjects, and protect military personnel from risks associated with HIV infection.			
FY 2015 Accomplishments: Conducted analysis of samples from safety and effectiveness clinical trial RV305 including extensive evaluation of binding antibodies based on previously determined correlates of protection. In addition, novel findings in the properties of some circulating antibodies prompted planning for an open label extension to start in FY15. Completed FY15 collection of invasive samples for safety and effectiveness clinical trials RV306 and RV328; those samples have a requirement for immediate processing and analysis. Concluded FY15 RV306 and 328 with costs associated with the five clinical trial sites associated with those protocols.			
FY 2016 Plans: In RV305 (a late boost study of RV144 vaccine recipients), coordinate final data analyses and meet with investigators as to how the data should be presented/published. Results of RV305 resulted in a rollover study (RV305 amendment) which provides an additional boost dose to selected vaccine recipients. Continue candidate vaccine trials RV306 (evaluation of different one-year boosts) and RV328 (study of AIDSVAX B/E alone) to produce further immunogenicity data that complement the RV305 data. Continue the RV403 in Mozambique, Uganda, and Thailand. Compare the studies of immune responses induced by the RV144 regimen using AIDSVAX B/E mixed with L(MPLA) [monophosphoryl lipid A) with liposomes.			
FY 2017 Plans: Will complete the rollover RV305 study (RV305 Amendment) to provide additional open-label boost to willing volunteers. Will conduct analysis of samples from RV305A study and will coordinate to analyze and evaluate data from the study. Will continue			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army	Date: February 2016
--	----------------------------

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 811 / <i>Mil HIV Vac&Drug Dev</i>
--	--	---

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2015	FY 2016	FY 2017
to seek further complementary immunogenicity (ability to provoke immune response) data from Candidate vaccine trials RV306 and RV328 and will complete the collection of samples for safety and effectiveness of the study. RV403 study will continue in Mozambique, Uganda, and Thailand with adjuvanted AIDSVAX B/E and will continue to collect samples from volunteers. IPT will continue to review Analysis of Alternatives (AoA) and disruptive technologies that have the potential to refocus current vaccine effort to a product that has a greater utility for military relevant populations. Down selection of viable vaccine candidates will be made in anticipation of a single phase IIB efficacy trial (trials to evaluate efficacy in patients with the disease) in FY18.			
Accomplishments/Planned Programs Subtotals	1.036	0.965	0.638

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

Test and evaluate commercially developed drug/vaccine candidates in government-managed trials.

E. Performance Metrics

N/A

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 811 / Mil HIV Vac&Drug Dev
--	---	--

Management Services (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Management Services Cost	TBD	Not Applicable : Not Applicable	2.118	0.146		0.110		0.119		-		0.119	Continuing	Continuing	Continuing
Subtotal			2.118	0.146		0.110		0.119		-		0.119	-	-	-

Remarks
Not Applicable

Product Development (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Cost	TBD	Not applicable : Not applicable	3.289	0.508		0.343		0.308		-		0.308	Continuing	Continuing	Continuing
Medical Product Development Support Cost	TBD	TBD : TBD	0.000	-		0.222		-		-		-	0	0.222	0
Subtotal			3.289	0.508		0.565		0.308		-		0.308	-	-	-

Support (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Support Cost	TBD	TBD : TBD	1.572	0.250		0.195		0.157		-		0.157	0	2.174	0
Subtotal			1.572	0.250		0.195		0.157		-		0.157	0.000	2.174	0.000

Remarks
Not Applicable

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 811 / Mil HIV Vac&Drug Dev
--	---	--

Test and Evaluation (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development T&E Cost	TBD	Not applicable : Not Applicable	15.776	0.132		0.095		0.054		-		0.054	0	16.057	0
Subtotal			15.776	0.132		0.095		0.054		-		0.054	0.000	16.057	0.000

Remarks
Not Applicable

	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	22.755	1.036	0.965	0.638	-	0.638	-	-	-

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 811 / <i>Mil HIV Vac&Drug Dev</i>
--	--	---

Event Name	FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020				FY 2021			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
	RV305A Amendment to add open-label boost to volunteers					FY 15-FY17																						
RV306 Intensive Immune Monitoring of Prime-Boost Vaccine																												
RV328 Intensive Immune Monitoring of AIDS VAXB/E alone					FY 12-FY15																							
RV403 to evaluate adjuvant's ability to enhance durability					FY 12-FY18																							
RV Candidate Cohort development for efficacy studies													FY 15-FY19															
RV Candidate Immune Characterization for protective immunity													FY 16-FY18															
																					FY 19-FY22							

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 811 / <i>Mil HIV Vac&Drug Dev</i>
--	--	---

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
RV305A Amendment to add open-label boost to volunteers	3	2015	2	2017
RV306 Intensive Immune Monitoring of Prime-Boost Vaccine	2	2011	4	2015
RV328 Intensive Immune Monitoring of AIDSVAXB/E alone	4	2014	1	2018
RV403 to evaluate adjuvant's ability to enhance durability	2	2015	3	2019
RV Candidate Cohort development for efficacy studies	4	2016	4	2018
RV Candidate Immune Characterization for protective immunity	1	2019	2	2022

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army										Date: February 2016		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>			
COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
836: <i>Field Medical Systems Advanced Development</i>	-	12.819	15.000	17.951	-	17.951	13.544	13.034	16.134	16.565	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

Note

Not applicable for this PE.

A. Mission Description and Budget Item Justification

This project funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project funds human clinical trials to test the safety and effectiveness of biologics (products derived from living organisms) and devices necessary to meet medical requirements. When available, commercial-off-the-shelf (COTS) medical products are also tested and evaluated for transition to engineering and manufacturing development. Consideration is also given to reducing the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2015	FY 2016	FY 2017
Title: Field Medical Systems Advanced Development - PM Medical Devices	11.285	11.760	14.763
Description: Advanced Concept Development funding is provided for the following development of medical devices in support of enhanced combat casualty care.			
FY 2015 Accomplishments: Eye Tracking System for Assessing Concussions (system is a traumatic brain injury diagnostic tool): Noninvasive neurodiagnostic technologies for TBI is multi-focused. The Eye Tracking System for Assessing Concussions (system is a traumatic brain injury diagnostic tool) is one of multiple systems to be evaluated. All non-invasive technologies were collated under one integrated IPT. The technologies involved were Neurocognitive Assessment Tools and Eye-Tracking Systems. Future components of the multi-focused approach fall under the scope of this line item (i.e. quantitative electroencephalography (qEEG), near-infrared spectroscopy (NIRS), vestibular, etc.). TBI Diagnostic Assay System Increment II Point of Care Device: TBI Diagnostic Assay System: The focus of this effort was to use the current Biomarker technology developed by Banyan and cross-level all known technologies to Abbott Diagnostics. Contracting efforts were put in place to facilitate this path forward. Army uses the i-STAT in assemblages. The effort modernized the i-STAT platform to accommodate the new cartridges associated with the TBI Biomarkers. Impedance Threshold Device for the Treatment of TBI: Current device has a 510(k) (Pre-market Notification) clearance for multiple indications. Continued the submission of a new 510(k) planned to cover the expanded indications for the currently fielded device. Device will no longer be a stand-alone product, because the capability will be incorporated in existing ventilators. Compartment			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army		Date: February 2016		
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2015	FY 2016	FY 2017
<p>Syndrome Pressure Device: Transitioned from project 840 6.3 funding and enrolled patients in the pivotal trial for FDA clearance for anticipated FY15 start of the clinical trial.</p> <p>FY 2016 Plans: TBI Diagnostic Assay System Increment II Point of Care Device: TBI Diagnostic Assay System: Continue current Biomarker technology developed by Banyan and coordinate all known technologies to Abbott Diagnostics. Continue contracting efforts in FY16. Impedance Threshold Device for the Treatment of TBI: Product has transitioned back to S&T to conduct research on the expanded indications for the fielded device. Compartment Syndrome Pressure Device: Compartment Syndrome Pressure Device will be delayed for transition into Advanced Development from S&T until FY17. Milestone A will be delayed until FY17. After the Milestone A, product will transition into Advanced Development. Junctional / Noncompressible Hemorrhage Control Agent: The plan is for the product to transition into Advanced Development after Milestone B in late FY15. If FDA requires 510-K, program will develop required paper work for submission to the FDA.</p> <p>FY 2017 Plans: TBI Diagnostic Assay System Increment II Point of Care Device: Will continue to focus on the current Biomarker technology developed by Banyan and platform development with Abbott Diagnostics. Compartment Syndrome Pressure Device: Prior testing results will determine the Materiel solution pathway. The materiel solution will transition in FY17 as previously expected. Junctional / Noncompressible Hemorrhage Control Agent: Will continue FY16 efforts to scope effort and requirements. Intrathoracic Pressure Regulation Therapy (IPRT) (Formally Ventilator Support Device): Will work on validation efforts and preclinical testing to achieve FDA 510(k) clearance of the device to enhance circulation with possible applications towards shock and head injury. Will perform testing to ensure the IPRT product is compatible with existing fielded systems. PTSD Biomarkers: Pending favorable research results in FY16, will begin prototype device development. Field Anesthesia: Pending refinement of Service and Joint requirements, will transition technology to PE 0604807A Project 832. Ocular Drug Delivery (Ocular Salvage Device): Will determine products to move forward to clinical trials based on results from bench and preclinical studies. Portable Extracorporeal Membrane Oxygen (ECMO): Will evaluate development of more compact, portable and less invasive product from existing ECMO vendors.</p>				
<p>Title: Field Medical Systems Advanced Development - PM Medical Support Systems</p> <p>Description: Funding is provided for the following effort in the development of products that support the medical mission in combat casualty care and health care operations.</p> <p>FY 2015 Accomplishments: Medical Evac and Treatment Vehicles Medical Equipment Set and Mission Essential Package: Continued collaboration with Program Executive Office Combat Support/Combat Service Support (PEO CS&CSS) and Program Executive Office Ground Combat Systems (PEO GCS) on development efforts for emerging medical vehicle evacuation/casualty evacuation (CASEVAC)</p>		1.534	3.240	3.188

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army		Date: February 2016
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2015	FY 2016	FY 2017
<p>variants. Improved Vector Tent Traps: Continued prototype development of Vector Tent Traps and transitioned to project 832. Altitude Readiness Management System (ARMS): Continued prototype development of the Altitude Readiness Management System (ARMS) and transitioned to project 832. Next Generation Uniform Repellent: Began development of the Next Generation Uniform Repellent (NGUR). The NGUR transitioned from an S&T SBIR. The NGUR is an effort to develop new military uniform insect repellent formulations for the uniform materiel and the corresponding uniform treatment technology. Next Generation Immobilization System: Transitioned from S&T SBIR. Developed prototypes for initial developmental testing and FDA data collection. The Next Generation Immobilization System (NGIS) provided advanced vibration dampening to allow for safer evacuation of spinal cord injury and traumatic brain injury casualties. Hydration Status Monitor (HSM): Hydration Status Monitor (HSM) transition continued to be delayed. Milestone B for this effort is scheduled for Feb 2015. Contract is planned to be a 4 year effort to develop the actual device and gain FDA approval for use.</p> <p>FY 2016 Plans: Medical Evac and Treatment Vehicles Medical Equipment Set and Mission Essential Package: Continue collaboration with Program Executive Office Combat Support/Combat Service Support (PEO CS&CSS) and Program Executive Office Ground Combat Systems (PEO GCS) on development efforts for emerging medical vehicle evacuation/casualty evacuation (CASEVAC) variants including AMPV source selection. Exploring CASEVAC kit development for MRAP Dash and JLTV vehicles. Transition to 832 in FY17. Improved Vector Tent Traps: Continue prototype development of Vector Tent Traps and transition to project 832. Next Generation Uniform Repellent: Continue development of the Next Generation Uniform Repellent/Impregnation process in collaboration with PEO Soldier. Obtain EPA registration. Perform cut and sew testing of EPA approved uniform repellent/impregnation process for permethrin. Investigate use of other repellents. Next Generation Immobilization System (NGIS): Continue prototype development of NGIS and begin initial developmental tests and user evaluations. Hydration Status Monitor (HSM): Hydration Status Monitor (HSM) transition will be delayed due to a more extensive feasibility study than initially determined. Initiate development of prototype devices and prepare for the Milestone B submission with required documentation.</p> <p>FY 2017 Plans: Medical Evacuation and Treatment Vehicles, Medical Equipment Set and Mission Essential Package, and CASEVAC: Will transition to project PE 0604807A Project 832. Improved Flying Vector Trap (IFVT) (formerly Improved Vector Test Traps). Will transition to PE 0604807A Project 832. Next Generation Uniform Repellent/Impregnation: Will continue development of the Next Generation Uniform Repellent/Impregnation process in collaboration with PEO Soldier. Will obtain Environmental Protection Agency (EPA) registration on a different repellent and evaluate integration into the uniform manufacturing process. Litter Transport Shock/Stressor Mitigation System (formerly Next Generation Immobilization Systems (NGIS). Will finalize prototype design for transition to PE 0604807A Project 832 to conduct developmental test and user evaluations. Remote Triage Sensor System: Will</p>			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army		Date: February 2016
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2015	FY 2016	FY 2017
transition the Remote Triage Sensor System from a Small Business/Innovative Research (SBIR) effort to PE 0604807A Project 836. Will finalize development of a fully functional prototype in preparation for developmental and user evaluations.			
Accomplishments/Planned Programs Subtotals	12.819	15.000	17.951

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.

E. Performance Metrics

N/A

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 836 / Field Medical Systems Advanced Development
--	---	--

Management Services (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development Management Services Cost	Various	Not Applicable : Not applicable	40.255	0.933		0.623		3.124		-		3.124	Continuing	Continuing	Continuing
TBI Diagnostic Assay System - Increment II (benchtop/POC/ Bandits)	TBD	Banyan BioMarkers, Inc : Alachua FL	0.208	-		-		-		-		-	0	0.208	0
Impedance Threshold Device for the Treatment of Traumatic Brain Injury	TBD	Advance Circulatory Systems, Inc : Roseville, MN	0.154	-		-		-		-		-	0	0.154	0
Subtotal			40.617	0.933		0.623		3.124		-		3.124	-	-	-

Product Development (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Product Development	TBD	TBD : TBD	0.000	0.932		-		-		-		-	0	0.932	0
Medical Product Development	TBD	ALL Product : Various	1.931	-		-		2.083		-		2.083	Continuing	Continuing	Continuing
Product Development of Freeze-dried plasma	TBD	TBD : TBD	2.400	6.378		-		-		-		-	Continuing	Continuing	Continuing
Point of Care Coagulation Profiler	TBD	TBD : TBD	0.000	-		0.385		-		-		-	0	0.385	0
TBI Diagnostic Assay System - Increment II (benchtop/POC/ Bandits)	TBD	Banyan BioMarkers, Inc : Alachua FL	6.737	-		6.614		3.200		-		3.200	0	16.551	0
Impedance Threshold Device for the Treatment of Traumatic Brain Injury	TBD	Advance Circulatory Systems Inc. : Roseville, MN	2.322	-		-		-		-		-	0	2.322	0
Compartment Syndrome Pressure Device	TBD	Twinstar : Minneapolis, MN	0.000	1.871		-		-		-		-	0	1.871	0
Hydration Status Monitor	TBD	Gaia Medical : LaJolla CA	0.000	0.841		-		-		-		-	0	0.841	0

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 836 / Field Medical Systems Advanced Development
--	---	--

Product Development (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Noninvasive Neuromodulator TBI	TBD	TBD : TBD	0.000	-		2.140		-		-		-	0	2.140	0
PTSD	Various	TBD : Various locations	0.000	-		-		2.532		-		2.532	0	2.532	0
Ocular Salvage Device	Various	TBD : TBD	0.000	-		-		2.479		-		2.479	0	2.479	0
Field Anesthesia	TBD	TBD : Various	0.000	-		-		3.068		-		3.068	0	3.068	0
Field Sterilizer	TBD	TBD : TBD	0.000	-		3.815		-		-		-	0	3.815	0
Product Development	TBD	HemCon Medical Technologies : Tigard, Oregon	9.720	-		-		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	Banyan BioMarkers, Inc : Alachua FL	31.514	-		-		-		-		-	Continuing	Continuing	Continuing
Development of Platelet Derived Hemostatic agent	TBD	Fast Track Drugs & Biologics : Frederick, MD	1.800	-		-		-		-		-	Continuing	Continuing	Continuing
Subtotal			56.424	10.022		12.954		13.362		-		13.362	-	-	-

Support (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Medical Product Development Support Cost	Various	Not Applicable : Not applicable	44.065	0.932		0.723		0.744		-		0.744	Continuing	Continuing	Continuing
Subtotal			44.065	0.932		0.723		0.744		-		0.744	-	-	-

Remarks
No product/contract costs greater than \$1M individually.

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev	Project (Number/Name) 836 / Field Medical Systems Advanced Development
--	---	--

Test and Evaluation (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost			
Medical Product Development T&E Cost	TBD	Not applicable : Not applicable	36.061	0.932		0.700		0.721		-		0.721	Continuing	Continuing	Continuing
Subtotal			36.061	0.932		0.700		0.721		-		0.721	-	-	-

Remarks
No product/contract costs greater than \$1M individually.

	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	177.167	12.819	15.000	17.951	-	17.951	-	-	-

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>
--	--	---

Event Name	FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020				FY 2021			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
(1) Hydration Status Monitor MS-B					1 MS-B																				2 MS-B			
(2) Ocular Salvage Device					3 MS-B																				3 MS-B			
(3) Alternative Pain Delivery Device					4 MS-B																				4 MS-B			
(4) Burn Polymer Cover Device																												

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2017 Army		Date: February 2016
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) 836 / <i>Field Medical Systems Advanced Development</i>

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Hydration Status Monitor MS-B	4	2015	4	2015
Ocular Salvage Device	2	2021	2	2021
Alternative Pain Delivery Device	2	2021	2	2021
Burn Polymer Cover Device	1	2021	1	2021

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army										Date: February 2016		
Appropriation/Budget Activity 2040 / 4					R-1 Program Element (Number/Name) PE 0603807A / Medical Systems - Adv Dev				Project (Number/Name) VS7 / MEDEVAC Mission Equipment Package (MEP) - Adv Dev			
COST (\$ in Millions)	Prior Years	FY 2015	FY 2016	FY 2017 Base	FY 2017 OCO	FY 2017 Total	FY 2018	FY 2019	FY 2020	FY 2021	Cost To Complete	Total Cost
VS7: MEDEVAC Mission Equipment Package (MEP) - Adv Dev	-	0.269	0.000	0.000	-	0.000	0.000	0.000	0.000	0.000	0.000	0.269
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

Note

Medical Evacuation Enroute Care Validation Study is completed in FY 2015. Products from this project transition to PE 0604807A Project VS8 in FY 16.

A. Mission Description and Budget Item Justification

Original models of Army Black Hawk MEDEVAC helicopters continue to play a major role in maintaining high US troop survival rates in Iraq and Afghanistan by evacuating wounded troops in less than one-hour. In 2009 a VCSA-approved force design update increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operational needs. In 2010, the AMEDD accepted life-cycle management of the MEDEVAC MEP from PEO Aviation. In order to achieve required operational capability and enhance commonality across the MEDEVAC fleet, the MEDEVAC MEP program upgrades, retrofits, trains, and sustains the 256 MEDEVAC legacy helicopters to achieve the medical capability provided by the HH-60M, which is factory built for the MEDEVAC mission.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2015	FY 2016	FY 2017
Title: Medical Evacuation Enroute Care Validation Study	0.269	-	-
Description: Medical Evacuation Enroute Care Validation Study			
FY 2015 Accomplishments: Modified Interim MEDEVAC Mission Support System (IMMSS) to take into account the new paramedic skills being used by the flight paramedic.			
Accomplishments/Planned Programs Subtotals	0.269	-	-

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

Develop in-house or industrial prototypes in government-managed programs to meet military MEDEVAC and regulatory requirements for production and fielding.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2017 Army		Date: February 2016
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) VS7 / <i>MEDEVAC Mission Equipment Package (MEP) - Adv Dev</i>

E. Performance Metrics

N/A

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army												Date: February 2016				
Appropriation/Budget Activity				R-1 Program Element (Number/Name)				Project (Number/Name)								
2040 / 4				PE 0603807A / Medical Systems - Adv Dev				VS7 / MEDEVAC Mission Equipment Package (MEP) - Adv Dev								
Management Services (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
Medical Product Development Management Services Cost	TBD	APM MEDEVAC : Huntsville, AL	0.189	-		-		-		-		-	0	0.189	0	
Subtotal			0.189	-		-		-		-		-	0.000	0.189	0.000	
Product Development (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
Medical Product Development Cost	TBD	APM MEDEVAC PEO Aviation : Huntsville AL	1.479	-		-		-		-		-	0	1.479	0	
Subtotal			1.479	-		-		-		-		-	0.000	1.479	0.000	
Support (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
Medical Product Development Support Cost	TBD	APM MEDEVAC : Huntsville, AL	0.642	0.269		-		-		-		-	0	0.911	0	
Subtotal			0.642	0.269		-		-		-		-	0.000	0.911	0.000	
Test and Evaluation (\$ in Millions)				FY 2015		FY 2016		FY 2017 Base		FY 2017 OCO		FY 2017 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
Medical Product Development T&E Cost	MIPR	APM MEDEVAC PEO Aviation : Huntsville, AL	0.199	-		-		-		-		-	0	0.199	0	
Subtotal			0.199	-		-		-		-		-	0.000	0.199	0.000	

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2017 Army								Date: February 2016			
Appropriation/Budget Activity 2040 / 4				R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>				Project (Number/Name) VS7 / <i>MEDEVAC Mission Equipment Package (MEP) - Adv Dev</i>			
	Prior Years	FY 2015		FY 2016		FY 2017 Base	FY 2017 OCO	FY 2017 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	2.509	0.269		0.000		-	-	-	0.000	2.778	0.000

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2017 Army **Date:** February 2016

Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) VS7 / <i>MEDEVAC Mission Equipment Package (MEP) - Adv Dev</i>
--	--	--

Event Name	FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020				FY 2021			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
Telemedicine Research and Development and Tech Transfer	Research and development																											

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2017 Army		Date: February 2016
Appropriation/Budget Activity 2040 / 4	R-1 Program Element (Number/Name) PE 0603807A / <i>Medical Systems - Adv Dev</i>	Project (Number/Name) VS7 / <i>MEDEVAC Mission Equipment Package (MEP) - Adv Dev</i>

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Telemedicine Research and Development and Tech Transfer	1	2015	4	2015